Population Norms News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Population norms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Population Norms Today - Breaking & Trending Today

Significant Fatigue Common in Adult Patients with Sickle Cell Disease

A lower FACIT-Fatigue score, indicating higher fatigue was independently associated with female sex, a high BMI, a high stress level, and poor sleep quality. ....

Value Health , Lancet Haematology Commission , Functional Assessment , Chronic Illness Therapy , Lancet Haematology , Population Norms , Chronic Illness Therapy Fatigue , Patient Rep ,

"Australian population norms for health-related quality of life measure" by Lisa Redwood, David Currow et al.

Background: Measuring health related quality-of-life (HRQoL) of the general population is essential to establish a reference for health outcome evaluations. This study sought to establish EQ-5D-5L population norms in Australia and to investigate the heterogeneity of HRQoL between sociodemographic variables. Methods: A cross-sectional study comprising of a representative sample of Australia’s general population (n = 9958) aged 18 or older. Recruitment quotas were set for the Australian census population by age, sex, state/territory of residence and rurality. Participants were recruited by Qualtrics through its database of over 800,000 registered panel members and asked to value their own state of health using the EQ-5D-5L domains and the EuroQol-Visual Analogue Scale (EQ-VAS). An Australian value set developed using Discreet Choice Experiment was used to calculate utility scores. Results: The estimated mean EQ-5D-5L index for Australia’s general population was 0.86 (standard deviati ....

Euroqol Visual Analogue Scale , Discreet Choice Experiment , Eq Vas , Q 5d 5l , Ealth Related Quality Of Life , Population Norms , Reference Values ,

Novartis Phase III APPOINT-PNH trial shows investigational

Data at EBMT show primary endpoint met – estimated 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2. ....

South Korea , United States , France General , Sloan Simpson , Parag Mahanti , Ann Hematol , Richard Jarvis , Iptacopan Monotherapy , Isabella Zinck , Samir Shah , Nicole Zinsli Somm , Mary Carmichael , David Soergel , Satoshi Sugimoto , Julie Masow , Michael Meo , Giuseppe Moscati , Antonio Risitano , Marlena Abdinoor , Value Health , Greater Paris University Hospital , Interest Group , Novartis Institutes For Biomedical Research , Metabolism Development Unit , Exchange Commission , Reference Center ,

Novartis Pharma AG: Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

Data at EBMT show primary endpoint met - estimated 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline ....

South Korea , France General , United States , Satoshi Sugimoto , Julie Masow , Giuseppe Moscati , Samir Shah , David Soergel , Ann Hematol , Mary Carmichael , Antonio Risitano , Iptacopan Monotherapy , Marlena Abdinoor , Michael Meo , Nicole Zinsli Somm , Isabella Zinck , Richard Jarvis , Sloan Simpson , Parag Mahanti , Value Health , Metabolism Development Unit , Greater Paris University Hospital , European Medicines Agency , Novartis Institutes For Biomedical Research , Interest Group , Novartis Pharmaceuticals ,